Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - polysaccharida neisseriae meningitidis c (stamm c11,-o-acetyliert), toxoidum tetani - injektionssuspension - polysaccharida neisseriae meningitidis c (stamm c11, de-o-acetyliert) 10 µg conjugatum cum toxoidum tetani 10-20 µg, aluminium ut aluminii hydroxidum hydricum ad adsorptionem, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen meningokokken der serogruppe c, ab dem vollendeten 2. lebensmonat - impfstoffe

Europäische Union - Deutsch - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokken - impfstoffe - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

swedish orphan biovitrum ag - pegcetacoplanum - infusionslösung - pegcetacoplanum 54 mg, sorbitolum 41 mg, acidum aceticum glaciale, natrii acetas trihydricus, natrii hydroxidum, acidum aceticum glaciale, aqua ad iniectabile, ad solutionem pro 1 ml corresp. natrium 0.37 mg. - paroxysmale nächtliche hämoglobinurie (pnh). - synthetika